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Recombinant adeno-associated virus vectors are an increasingly popular tool for gene
delivery to the CNS because of their non-pathological nature, low immunogenicity, and
ability to stably transduce dividing and non-dividing cells. One of the limitations of
rAAVs is their preferential tropism for neuronal cells. Glial cells, specifically astrocytes,
appear to be infected at low rates. To overcome this limitation, previous studies utilized
rAAVs with astrocyte-specific promoters or assorted rAAV serotypes and pseudotypes
with purported selectivity for astrocytes. Yet, the reported glial infection rates are not
consistent from study to study. In the present work, we tested seven commercially
available recombinant serotypes– rAAV1, 2, and 5 through 9, for their ability to transduce
primary rat astrocytes [visualized via viral expression of green fluorescent protein (GFP)].
In cell cultures, rAAV6 consistently demonstrated the highest infection rates, while rAAV2
showed astrocytic transduction in some, but not all, of the tested viral batches. To verify
that all rAAV constructs utilized by us were viable and effective, we confirmed high
infectivity rates in retinal pigmented epithelial cells (ARPE-19), which are known to be
transduced by numerous rAAV serotypes. Based on the in vitro results, we next tested
the cell type tropism of rAAV6 and rAAV2 in vivo, which were both injected in the barrel
cortex at approximately equal doses. Three weeks later, the brains were sectioned and
immunostained for viral GFP and the neuronal marker NeuN or the astrocytic marker
GFAP. We found that rAAV6 strongly and preferentially transduced astrocytes (>90% of
cells in the virus-infected areas), but not neurons (∼10% infection rate). On the contrary,
rAAV2 preferentially infected neurons (∼65%), but not astrocytes (∼20%). Overall, our
results suggest that rAAV6 can be used as a tool for manipulating gene expression
(either delivery or knockdown) in rat astrocytes in vivo.
Keywords: adeno-associated virus, AAV2, AAV6, astrocytes, brain, in vivo
INTRODUCTION
Viral vectors are widely used for gene delivery and manipulation of gene expression within
the CNS. Among them, adeno-associated viruses (AAVs) have become increasingly popular
due to their non-pathogenicity, low propensity to induce innate immune responses, ability to
effectively transduce dividing and non-dividing cells and produce long-lasting gene expression
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(Kaplitt et al., 1994; Wu et al., 2006b; Weinberg et al., 2013;
Salganik et al., 2015). The efficacy of AAV constructs in basic and
pre-translational studies led to their successful introduction into
clinical practice, including applications in the CNS. Over the past
decade, recombinant AAVs have been utilized for gene delivery
in clinical trials targeting the brain, spinal cord, and retinal
tissue (reviewed in Surace and Auricchio, 2008; Lentz et al.,
2012; Weinberg et al., 2013; Bartus et al., 2014). The encouraging
safety profile of rAAV human gene therapies, including those
tested in the CNS, and the effective phenotypic correction in
several human monogenic disorders reinforced the appeal of this
approach and further increased the utilization of rAAVs in basic
science studies.
Adeno-associated viruses are a small, non-enveloped viral
species belonging to the Dependovirus genus within the family
of parvoviruses. They require helper viruses, such as adenovirus
or herpes virus, for successful replication. The simple AAV
genome consists of two inverted terminal repeat regions (ITR)
that flank the main open reading frames of the linear, single-
stranded DNA totaling approximately 4.7 kb. The rep part of the
genome encodes four proteins responsible for viral replication
and site-specific chromosomal integration; an additional cap
open reading frame is responsible for production of three
different capsid proteins [reviewed in (Wu et al., 2006b; Daya
and Berns, 2008; Salganik et al., 2015)]. In the recombinant
AAVs used for research and clinical purposes, the rep and cap
parts of the genome are removed and replaced with the ITR-
flanked constructs encoding gene(s) of interest and/or shRNA-
generating constructs, plus antibiotic-resistance genes that are
required for selection. Therefore, packaging of recombinant
AAVs requires additional plasmids encoding rep genes (typically
derived from AAV2) and cap genes assorted from various AAV
serotypes or genetically redesigned to modify capsid properties,
as well as the helper plasmid providing adenoviral helper genes
(Gao et al., 2005; Wu et al., 2006b; Kotterman and Schaffer,
2014).
The variability of AAV capsid proteins determines very strong
differences between serotypes and pseudotypes in terms of their
cell type and tissue tropism. The prototypical AAV2 gains access
to target cells by binding to heparan sulfate proteoglycan and
via additional interaction with co-receptors, such as integrins
αVβ5, αVβ1, hepatocyte growth factor, and laminin (reviewed in
Wu et al., 2006b; Daya and Berns, 2008; Asokan et al., 2012).
Cellular surface receptors contributing to infection by other AAV
serotypes are less studied, but thought to involve either sialic
acid- or galactose-containing proteoglycans (Asokan et al., 2012).
A very recent publication identified the orphan transmembrane
protein KIAA0319L as a universal and indispensable AAV
receptor for several common AAV serotypes, including AAV6,
suggesting that further progress in our understanding of the
mechanisms of cell entrance should be expected (Pillay et al.,
2016).
Astrocytes are the most numerous and functionally complex
cells in the CNS that critically contribute to normal brain
functions and numerous neurological disorders (Sofroniew and
Vinters, 2010; Parpura et al., 2012). With increased appreciation
and evolving interest in normal and pathological roles for this
class of glial cells, there is a growing demand for viral vectors
effectively targeting astroglia (Merienne et al., 2013). Yet, the
majority of past studies have focused on rAAV transduction of
neuronal cells. The most frequently utilized serotype, rAAV2,
targets neurons nearly exclusively in rodents and in non-human
primates (see for example Kaplitt et al., 1994; Burger et al.,
2004; Dodiya et al., 2010, and reviews by Tenenbaum et al.,
2004; Weinberg et al., 2013). The same transduction patterns
were reported for rAAV1, 5, 8, and 9 (Burger et al., 2004;
Cearley and Wolfe, 2006; Dodiya et al., 2010; Markakis et al.,
2010). In contrast, other publications identified moderate-to-
strong tropism for astrocytes in studies with rAAV1, 5, 8, and
9 (Davidson et al., 2000; Foust et al., 2009; Gray et al., 2011;
Aschauer et al., 2013; Petrosyan et al., 2014; Watakabe et al.,
2015), or even preferential astrocytic transduction by rAAV8
and rAAV-rh43 (Lawlor et al., 2009; Aschauer et al., 2013). The
reasons for variability in glial tropism of AAV serotypes are
still poorly understood (see “Discussion” for further details).
Some refinements in glial specificity have been made with
incorporation of the astrocyte-specific promoters, such as gfa2
or gfaABC1D (Merienne et al., 2013; Weinberg et al., 2013).
However, even with these improvements, astrocytic transduction
rates appear to be moderate and new AAV vectors targeting
astroglial cells would be a welcome addition to the field.
Here, we report that one of the less studied rAAV serotypes,
rAAV6, potently and preferentially targets astrocytes in the rat
cortex.
MATERIALS AND METHODS
Materials and Reagents
Bovine serum albumin (BSA), 4′,6-diamidino-2-phenylindole
dihydrochloride (DAPI), N-propyl-gallate, Triton X-100, all
salts and solvents were purchased from Sigma–Aldrich (St.
Louis, MO, USA), unless otherwise specified, and were of the
highest purity available. Cell culture media, sera, antibiotics
of the Gibco R© brand, and the recombinant protease TrypLE
R©
were acquired from Life Technologies/Thermo Fisher Scientific
(Waltham, MA, USA). The sources and catalog numbers for
all used antibodies are provided as they appear first in the
text.
rAAV Vectors
Recombinant AAVs – serotypes rAAV1, rAAV2, rAAV5, rAAV6,
rAAV7, rAAV8, and rAAV9 – were acquired from ViGene
Biosciences (Rockville, MD, USA). Each of these viral constructs
were prepared using triple-plasmid transfection of HEK293 cells.
The main pAV-U6-GFP plasmid contained AAV2 ITRs, the
shRNA insertion site under control of the U6 promoter, a
sequence encoding enhanced green fluorescent protein (EGFP)
under control of the distinct CMV promoter, and the ampicillin
resistance gene. Separate Rep/Cap plasmid and the helper
plasmid provided components of the viral replication machinery
and the capsid proteins of selected AAV serotypes. After
HEK293 cell lysis, rAAV particles were purified by iodixanol
gradient ultracentrifugation. Further details about these viruses
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and their packaging and purification can be found on the
company website1. As an additional control, we also used
rAAV1, rAAV2, rAAV5, and rAAV9 that were packaged at the
University of Massachusetts Medical School (Worcester, MA,
USA) according to the previously published method (Gao and
Sena-Esteves, 2012). The latter rAAVs were also generated by
a triple-plasmid transfection of HEK293 cells. These constructs
encoded EGFP under the control of the promoter containing the
cytomegalovirus immediate-early enhancer (CMV IE) and 260
nucleotides (-1261 to -1,001) of the chicken β-actin 6 promoter,
and their efficacy was validated in vivo in a recent study (Vincent
et al., 2014). The rAAVs were packaged with assorted capsid
proteins of the specified serotypes. Viral particles were purified
by CsCl gradient ultracentrifugation. At both facilities, rAAVs
were titered by quantitative polymerase chain reaction (qPCR)
and their purity was further verified by Coomassie Brilliant Blue
or silver protein staining after separation on SDS-polyacrylamide
gels.
Cell Cultures of Primary Rat Astrocytes
and Retinal Pigmented Epithelial Cells
(RPE)
Primary astrocyte cultures were prepared from the brains of
1–2-day old Sprague–Dawley rat pups as previously described
(Mongin et al., 2011). All animal procedures strictly conformed
to NIH Guidelines for Care and Use of Laboratory Animals
and were approved by the Institutional Animal Care and
Use Committee of the Albany Medical College. In brief,
rat pups were killed by rapid decapitation and their brains
harvested. The cortices were separated from the meninges
and hippocampi, and placed into ice-cold Opti-MEM. The
brain tissue was minced and enzymatically dissociated in a
solution containing equal parts of the recombinant protease
TrypLE and Opti-MEM, and additionally supplemented with
DNase I (1 mg/ml). Cell extraction with TrypLE was repeated
three times at 37◦C. The first extraction was discarded.
Dissociated cells from the last two extractions were combined
and sedimented by brief centrifugation at 1,000 × g. Cells
were re-suspended in Dulbecco’s modified Eagle minimum
essential medium (DMEM) containing 10% of heat inactivated
horse serum (HIHS), 50 U/mL penicillin, and 50 µg/mL
streptomycin, and then plated on poly-D-lysine coated T-75
culture flasks at the density of 200,000 cells per flask. The
primary astrocyte cultures were grown in DMEM-10% HIHS
plus antibiotics for 2–4 weeks in a humidified atmosphere of
5% CO2/balance air at 37◦C. Cell culture media were changed
twice per week. Culture purity was >95% as periodically verified
by staining with antibody recognizing the astrocytic marker
glial fibrillary acidic protein (anti-GFAP, Sigma–Aldrich, catalog
#G3893).
Human RPE (ARPE-19, gift of Dr. Sally Temple, New York
Neural Stem Cell Institute, Rensselaer, NY, USA, passage
unknown) were used as an additional control for AAV efficacy.
They are known to be readily transduced with a variety of AAV
1http://www.vigenebio.com/
serotypes and pseudotypes (Surace and Auricchio, 2008). ARPE-
19 were cultivated in DMEM supplemented with 10% of fetal
bovine serum (FBS) and antibiotics in T75 flasks as described
above. They were periodically passaged after detachment with
TrypLE.
In vitro rAAV Infection and
Immunocytochemical Procedures
Primary astrocytes or ARPE-19 cells were plated in poly-D lysine
coated 24-well plates with glass bottoms at a sub-confluent
density and transduced with seven different rAAV vectors. Based
on the pilot titration experiments, we selected a viral titer of
105 genome copies per cell (gc/cell) to produce near maximal
infection rates. Cells were incubated with individual rAAVs in
Opti-MEM at 37◦C. After the initial 4-h incubation, each well was
supplemented with an equal volume of DMEM-10% HIHS for
astrocytes or DMEM-10% FBS for ARPE-19. After an additional
20 h, rAAV-containing media were replaced with fresh DMEM-
HIHS or DMEM-FBS as appropriate. Viral transduction rates
(GFP expression) were determined after 48–72 h.
To quantify transduction rates, cells were washed twice from
culture media with phosphate-buffered saline (PBS) and fixed
at room temperature (20◦C) using 4% paraformaldehyde in
PBS. After fixation they were washed again twice with PBS and
permeabilized with 0.1% Triton X-100 in PBS for 15 min at
room temperature. After two additional washes with PBS, cells
were blocked with 1% BSA in PBS for 1 h at room temperature.
For immunostaining, fixed astrocytes were incubated 1 h
at room temperature with either rabbit polyclonal anti-GFP
antibody (Life Technologies/Thermo Fisher Scientific, catalog
# A6455, 1:2,000) or chicken polyclonal anti-GFP antibody
(Life Technologies/Thermo Fisher Scientific, catalog #A10262,
1:500 dilution). Unbound primary antibodies were removed by
three 5-min washes in PBS, and cells were incubated with goat
anti-rabbit secondary antibody conjugated to Alexa–Fluor 488
(Life Technologies/Thermo Fisher Scientific, A11008, 1:1,000
dilution) or goat anti-chicken secondary antibody conjugated
to Alexa–Fluor 488 (Life Technologies/Thermo Fisher Scientific,
cat. # A11039, 1:500 dilution) for 1 h at room temperature.
The excess of secondary antibodies was removed by three 5-
min washes with PBS, and cells were then counterstained with
DAPI (10 µg/ml) for 15 min at room temperature and washed
once with PBS. Alexa-488 fluorescence images were captured
with a Zeiss LSM510META confocal microscope (Carl Zeiss,
Oberkochen, Germany). To ensure validity of the comparisons of
GFP expression, all images were taken at identical exposure and
settings.
Animal Surgeries and rAAV Injection
Stereotaxic injection of rAAV constructs was performed under
anesthesia according to the procedure approved by the
Institutional Animal Care and Use Committee of the Albany
Medical College in strict adherence to NIH Guidelines for Care
and Use of Laboratory Animals. Five-week-old male Sprague–
Dawley rats weighing approximately 200 g were anesthetized
with isoflurane (5% for induction, 2% for maintenance) in
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30% O2/balance N2. Body temperature was monitored via a
rectal probe and maintained at 36.5–37◦C with a heating pad.
Animals were placed in a rodent stereotaxic frame (David Kopf
Instruments, Tujunga, CA, USA). Their scalp was additionally
anesthetized with subcutaneous local injection of Bupivacaine
(Hospira, Lake Forest, IL, USA) and a small scalp incision was
made to locate the bregma. Next, a small burr hole in the skull
just above the barrel cortex region (-2 mm anterior, +5 mm
lateral from the bregma) was made using a Microtorque II
drill (Harvard Apparatus, Holliston, MA, USA). A Hamilton
syringe containing either rAAV2 or rAAV6 was lowered 2.1 mm
below the dura and 1 µL of virus was injected at the rate of
0.2µL/min. After a 10-min wait period to ensure proper diffusion
of virus, the syringe was drawn 1 mm up and the second 1-
µL injection was made. The incision was closed using staples,
0.1 mg/kg Buprenorphine (Reckitt Benckiser Healthcare, Hull,
UK) was injected subcutaneously, and triple antibiotic ointment
was applied to the closed wound. The animals were additionally
given Buprenorphine twice daily for two days following the
surgery. They were kept for an additional 3 weeks to allow for
spread of the virus and expression of the marker protein GFP
before harvesting the brain.
Immunohistochemical Evaluation of Viral
Transduction
To assess viral transduction, we performed immunohisto-
chemical analysis of the rAAV-driven GFP expression. Rats
were given a lethal injection of sodium pentobarbital and
perfused intracardially first with a heparin solution in PBS,
followed by 4% paraformaldehyde solution in PBS. Brains were
removed and post-fixed in 4% paraformaldehyde for 24 h at
4◦C, then transferred into a 30% sucrose solution (4◦C) for
cryoprotection. After completing cryoprotection, brains were
mounted on a cryostat stage using Tissue-Tek O.C.T. compound
(Sakura Finetek, Torrance, CA, USA), frozen to -20◦C, and
sectioned into 25-µm sections using a Leica CM3050 cryostat
(Leica, Buffalo Grove, IL, USA). Sections were stored at -20◦C
in a cryoprotectant solution containing 50% Tris buffered saline
(TBS), 30% ethylene glycol, and 20% glycerol, until the staining
procedure.
Prior to staining, sections were washed five times for 5 min
with TBS and blocked for 30 min at room temperature in a
solution containing 3% normal goat serum (Vector Laboratories,
Burlingame, CA, USA) and 0.3% Triton X-100. They were next
incubated for 24–48 h at 4◦C with rabbit polyclonal anti-GFP
antibody (Life Technologies/Thermo Fisher Scientific, catalog #
A6455, 1:400) diluted in 3% normal goat serum. Next, the slices
were washed five times for 5 min with TBS and then incubated for
2 h at room temperature with goat anti-rabbit Alexa–Fluor 488
secondary antibody (Life Technologies/Thermo Fisher Scientific,
A11008, 1:400) diluted in 3% normal goat serum. To identify
which cell types were infected with AAV, we subsequently stained
the same sections with either the mouse monoclonal anti-NeuN
antibody (EMD-Millipore, cat. # MAB377, 1:500) or the mouse
monoclonal anti-GFAP antibody (Sigma Aldrich, cat. # G3893,
1:400). The staining procedure was identical to that described for
GFP, except that GFAP or NeuN immunoreactivity was visualized
with goat anti-mouse secondary antibody conjugated to Alexa–
Fluor 555 (Life Technologies/Thermo Fisher Scientific, cat. #
A21422, 1:400). The excess of secondary antibody was removed
with three additional 5-min washes with TBS. Brain sections
were then counterstained with 0.1 µg/mL of DAPI at room
temperature for 15 min, washed once with TBS, then mounted
on microscope slides with the anti-fade reagent N-propyl-gallate
and sealed with clear nail polish.
To ensure specificity of the signal, we periodically reversed
the order of application for primary antibodies and noticed that
when GFP antibodies were applied last, the resulting GFP signal
was stronger. Also, adding 0.3% Triton X-100 into solutions
of primary antibodies allowed for better antibody penetration
into the sections. It should be stressed that the quantitative
analyses of cellular tropism were performed under all of the
above described scenarios, and changes in the order of antibody
application did not impact conclusions on transduction efficacy
or cellular tropism. GFP (Alexa-488), GFAP and NeuN (Alexa-
555), and DAPI immunofluorescence images in the brain sections
were captured using a Zeiss LSM-510 Meta confocal microscope
at 250× magnification with the identical exposure and settings.
Half-brain images were taken using a Leica TCS SPE confocal
microscope at 15× magnification to visualize the full extent
of viral spread. A series of six individual images were stitched
together to make one representative image using the ImageJ
stitching software.
Data Analysis
For quantitative analysis of in vivo viral transduction,
representative immunohistochemistry images were “coded”
and analyzed by two investigators, who were blinded to the
type of treatment (DG and AM), and additionally by the
primary investigator (ALS). The individual cell counts for each
stained section/IHC image were averaged among the three
investigators and then the average values of cell counts for
each immunohistochemical marker and the % fractions of the
virus-infected neuronal and astroglial cells were statistically
compared between treatment groups. Number of analyzed
sections, injected animals, and total cell counts are given in the
text and figure legends. The statistical comparisons between
groups were performed using ANOVA and Tukey post hoc
test for multiple comparisons in Origin 8.1 software suite
(OriginLabs, Northampton, MA, USA).
RESULTS
Among Seven Commonly Used rAAV
Serotypes, rAAV6 Has High Tropism for
Rat Primary Astrocytes In vitro
In order to identify an AAV serotype that effectively infects
astrocytes, we tested several commercially available recombinant
AAV vectors: rAAV1, rAAV2, rAAV5, rAAV6, rAAV7, rAAV8,
and rAAV9, all of which expressed the GFP protein under
the CMV promoter. In the first series of experiments, only
rAAV6 demonstrated consistent and high levels of astrocytic
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FIGURE 1 | Transduction of primary rat astrocytes with seven different rAAV-green fluorescent protein (GFP) viruses. Astrocytes were transduced with
105 gc/cell of either rAAV1, rAAV2, rAAV5, rAAV6, rAAV7, rAAV8, or rAAV9, or treated identically without the addition of virus (non-transfected), for 48 h. Results for
rAAV1, rAAV2, rAAV5, and rAAV6 are shown in the top two rows and results for rAAV7, rAAV8, rAAV9 and non-transfected astrocytes are shown in the bottom two
rows. Cells were stained with either rabbit or chicken anti-GFP antibodies, as indicated, and counterstained with 4′,6-diamidino-2-phenylindole dihydrochloride
(DAPI) to visualize GFP-negative cells. Images were acquired using a confocal Zeiss LSM510 META microscope at 250× magnification, in the same cell preparation
with identical exposure settings. Scale bar = 50 µm. Arrowheads point to cells with non-astrocytic morphology that were transduced with rAAV. Results are
representative of at least nine wells and four independent experiments per transduction condition.
transduction as detected with two different anti-GFP antibodies
(Figure 1). As a specificity control, we immunostained non-
transfected cells with the same two antibodies and detected
no immunoreactivity (Figure 1). Other tested rAAV serotypes
showed much lower levels of transduction with few GFP-positive
astrocytes and much lower fluorescence levels in individual
cells (Figure 1). Interestingly, rAAV7 and rAAV9, had an
apparent tropism toward secondary cell types (such as microglia
and O2A progenitors), which are present in primary astrocyte
cultures in small numbers (arrowhead labels in Figure 1). To
ensure that these results are replicable across different viral
preparations, we first performed the same experiment with a
second batch of viruses from the same vendor. In these latter
experiments, we observed high GFP expression in rAAV6- but
also in rAAV2-transduced astrocytes, pointing to differences
between viral batches (Supplementary Figure S1). Next, we
used an alternative set of viruses from a different packaging
facility and with a different promoter, and found high-to-
moderate levels of transduction with rAAV2 (AAV2/2) serotype,
and rAAV1 (AAV2/1) and rAAV5 (AAV2/5) pseudotypes,
respectively (Supplementary Figure S1). Due to a limited
amount of viral constructs, the results with AAV2/2, AAV2/1, and
AAV2/5 have not been repeated in several cell cultures, and no
alternative batches of these viruses were tested.
All experiments mentioned above were performed using the
same virus per cell ratio (105 genome copies/cell). Since we
saw dramatically different levels of transduction, we tested the
rAAV1, rAAV5, rAAV7-9 serotypes in the RPE line ARPE-19
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FIGURE 2 | Transduction of immortalized human retinal pigmented epithelial cell line (ARPE-19) with six different rAAV serotypes. ARPE-19 cells were
transduced with 105 gc/cell of either rAAV1, rAAV2, rAAV5, rAAV7, rAAV8, or rAAV9, as indicated, for 72 h. Infected cells were visualized with rabbit anti-GFP
antibodies, and counterstained with DAPI. Control non-transfected cells (NTF) were processed at the same time and in the same fashion. Images are representative
of three replicates and were captured using Zeiss LSM510 META confocal microscope at identical exposure settings at 250× magnification. Scale bars = 50 µm.
to ensure that they were fully functional. Retinal epithelial cells
are known to be readily transduced with a variety of AAV
serotypes and pseudotypes (Surace and Auricchio, 2008). We
utilized the same batches of rAAV and the same virus/cell ratio
as in the experiments presented in Figure 1. In strong contrast to
astrocytes, ARPE-19 cells demonstrated very high levels of GFP
expression with rAAV1, 2, 5, 8, and moderate infection rates with
rAAV7 and rAAV9 (Figure 2).
Altogether, in vitro experiments indicate that all viral
constructs, which were utilized in the present work, were fully
functional and that only rAAV6 consistently demonstrated strong
tropism toward astrocytes in vitro. Some but not all batches
of rAAV2, rAAV1, and rAAV5 also showed moderate levels of
astrocytic transduction. For rAAV2, differences were observed
even for different batches obtained from the same packaging
facility.
Effective In vivo Delivery of rAAV6 and
rAAV2 in the Rodent Cortex
We next tested if efficient astrocytic transduction by rAAV6
also occurred in vivo. We used rAVV2 as an additional control
because rAAV2 has been previously reported to preferentially
transduce neurons in vivo (reviewed in Tenenbaum et al.,
2004; Weinberg et al., 2013). As expected, our results showed
that rAAV2 produced low levels of astrocytic infection in cell
cultures. We injected rAAV6 or rAAV2 into the barrel cortex
of male Sprague–Dawley rats as described in the “Materials and
Methods.” It should be stressed that the same batches of virus
were used for all in vitro and in vivo experiments to avoid
potential impacts from inter-batch variability. The extent and
localization of viral transduction in the brain was visualized in
25-µm coronal sections using immunohistochemistry with an
FIGURE 3 | Transduction of GFP expression by rAAV2 and rAAV6 after
injection in rat cortex. Representative images from six different animals
were captured in proximity to the rAAV injection sites. Rats were injected with
either rAAV2 (top row) or rAAV6 (bottom row) as described in “Materials and
Methods.” Three weeks after injection, the brains were processed and 25-µm
coronal sections were stained with anti-GFP antibody and counterstained with
DAPI. Fluorescence signals were captured using a Leica TCS SPE confocal
microscope at 15× magnification and a series of six individual fields per each
brain were stitched together using the ImageJ software.
anti-GFP antibody and documented using confocal microscopy.
rAAV6 injection produced significant cell transduction, and the
virus tended to spread away from the site of injection (see
Figure 3 for serotype differences and the variability of the viral
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spread within each serotype). The rAAV6-transduced GFP signal
was detected up to 2 mm anterior and 2 mm posterior from
the site of injection (Supplementary Figure S2). rAAV2 also
induced robust cell transduction, but the viral signal tended to
concentrate closer to the site of injection (Figure 3), and did
not propagate further than 1–2 mm in the anterior-posterior
direction (Supplementary Figure S2). Although quantification
of the total volume of the rAAV-infected tissue was not one of
the objectives of this work, these latter results are consistent with
the literature reports indicating that rAAV2 spread in the rodent
and the primate brains is much smaller than those for other rAAV
serotypes (Burger et al., 2004; Taymans et al., 2007; Aschauer
et al., 2013; Watakabe et al., 2015).
Another significant difference between rAAV6 and rAAV2
was in the morphology of the infected cells. rAAV6 targeted
nearly exclusively astrocyte-like cells with smaller bodies and
highly branched, short processes (right panels in Supplementary
Figure S3). In contrast, rAAV2 targeted predominantly neuron-
like cells with larger cell bodies and long polarized projections
(left panels in Supplementary Figure S3), consistent with
its known affinity toward neurons (Tenenbaum et al., 2004;
Weinberg et al., 2013). In sum, both rAAV6 and rAAV2
successfully infected cortical brain tissue, and the rAAV-driven
GFP expression persisted for at least 3 weeks.
In the Rat Brain, rAAV6 Preferentially
Transduces Astrocytes While rAAV2
Targets Neurons
To elucidate which specific cell types were infected by rAAV6
and rAAV2, we double-stained additional brain sections for the
virally transduced GFP expression and either the neuron-specific
marker NeuN or the astrocyte-specific marker GFAP. As
expected, rAAV2 clearly transduced neuronal cells based on their
NeuN immunoreactivity and morphology (GFP+/NeuN+ cells
in Figure 4, AAV2 fields). In striking contrast, rAAV6 produced
little to no signal in NeuN+ cells (Figure 4, AAV6 fields). The
opposite was true, when virus-infected brains were stained for
the astrocytic marker GFAP. In rAAV2-infected animals, we
found very few GFP+/GFAP+ cells (Figure 5, AAV2 fields).
In the rAAV6-transduced brains, there was a nearly perfect
overlap between GFP and GFAP signals (Figure 5, AAV6 fields).
These data strongly suggest that rAAV2 has a clear preference
for neurons, while rAAV6 demonstrates strong tropism toward
astrocytes.
To quantify the cell tropism information, we performed
blinded counts of GFP+/NeuN+ and GFP+/GFAP+ cells in
5–8 representative microscopic fields at 250× magnification
(25× objective) in four animals injected with rAAV2 vs. four
animals injected with rAAV6. Two different viral batches of
each tested serotype were acquired from the same packaging
facility to ensure reproducibility of the data. In the rAAV2-
transduced brains, our counts identified 64.9 ± 5.5% of virus-
infected (GFP+) cells as neurons (218/336 cells), based on
the NeuN colocalization with GFP, while only 19.8 ± 6.3% of
the infected cells were GFP+/GFAP+ astrocytes (58/284 cells,
Figure 6). The majority of the remaining GFP+/NeuN- cells
were likely neurons too, based on their morphology (neuron-
like larger cell bodies and long processes, similar to those seen
in Figure 4, AAV2 fields). One possible reason for the apparent
underestimation of the rAAV2-transduced neurons is weak
NeuN immunoreactivity in a number of stained sections, which
made it difficult for blinded investigators to reliably identify
double-positive cells.
FIGURE 4 | Assessment of the ability of rAAV2 and rAAV6 to transduce neurons in the rat cortex. Slices were stained for GFP as a marker of viral
transduction (green), the neuronal marker NeuN (red), and DAPI (blue). The bottom right images in each set show overlay of all three signals, with shades of yellow
representing colocalization (at this magnification it is not obvious in some cells due to differences in signal intensities and cellular location). Z-stack images were
taken using Zeiss LSM510 META confocal microscope at 250× magnification and identical exposure settings. Scale bars = 50 µm. Images are representative of at
least 12 sections from four different rats for each virus.
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FIGURE 5 | Astrocytic tropism of rAAV2 and rAAV6 in the rat cortex. Slices were stained for GFP as a marker of viral transduction (green), the astrocytic
marker GFAP (red), and DAPI (blue). White arrows point to a few rAAV2-infected astrocytes (GFP+/GFAP+ cells for rAAV2). Although the vast majority of the AAV6
transduced cells were GFAP-positive, block arrows point to an exception, the rAAV6-transduced neuron-like cell (GFP+/GFAP- cell). Images were taken using a
Zeiss LSM510 META confocal microscope at 250× magnification. Scale bars = 50 µm. Images are representative of at least 12 sections from four different rats for
each virus.
Conversely, the rAAV6 viral construct transduced primarily
GFAP+ astrocytes. Cell counts established that 90.9 ± 2.8% of
GFP+ cells were astrocytes (241/265 counted cells, Figure 6,
and representative image in Figure 5, AAV6 fields). When the
AAV6-infected brains were counterstained with NeuN, we found
that only 10.8 ± 4.4% of GFP-expressing cells were neurons
(14/128 counted cells, Figure 6 and representative image in
Figure 4, AAV6 fields). The high tropism of rAAV6 for astrocytes
was consistently seen in four different animals injected with
two different batches of the virus. Counts of neurons and
astrocytes transduced by rAAV2 and rAAV6 differed significantly
(Figure 6).
DISCUSSION
The major finding of this study is that the commercially available
rAAV6 has high tropism for rat astrocytes in vitro and in vivo
and can fairly selectively transduce astrocytes in the rat cortex.
Among the seven tested rAAV serotypes only rAAV6 strongly
and consistently transduced astrocytes in primary cell cultures.
In vivo, rAAV6 transduced >90% of GFAP+ astrocytes in the
infected brain areas, with minimal infection of neuronal cells.
This is significant because the majority of currently available AAV
constructs do not readily target astroglial cells.
As already mentioned in the “Introduction,” the extensive
existing literature points to preferential neuronal tropism for
majority of rAAVs. Up to 95% of rAAV2-transduced cells
are typically counterstained with neuronal markers, and very
few are identified as astrocytes or other classes of glia (see
“Introduction” for references). Our present rAAV2 results are
consistent with the prior findings. Similar preferential neuronal
FIGURE 6 | Quantification of cell types transduced by either rAAV2 or
rAAV6. The data represent blinded analysis of randomly selected stained
sections from rat brains transduced with either rAAV2 or rAAV6. The data are
pooled from experiments using two different virus batches and four different
animals for each rAAV serotype. Colocalization of GFP and NeuN signals was
considered neuronal. Colocalization of GFP and GFAP signals was defined as
astrocytic. The data were analyzed by ANOVA with post hoc Tukey test for
multiple corrections and are presented as the means ± SEM (a total of 25
sections, 3+ different sections per brain, from four animals per viral construct).
∗∗p = < 0.01 between neurons and astrocytes transduced by the same
serotype or between the same cell type transduced by different serotypes.
transduction has been reported in the CNS of rodents and
non-human primates upon infusion of recombinant AAV1,
AAV5, AAV8, and AAV9 (see for example Wang et al., 2003;
Cearley and Wolfe, 2006; Taymans et al., 2007; Lawlor et al.,
2009; Dodiya et al., 2010). Yet, for unknown reasons, the
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findings of the preferential neuronal tropism for rAAVs are not
always consistent even within the same serotype. Moderate-to-
significant transduction of glial cells, predominantly astrocytes,
was seen in rodents and non-human primates injected with
rAAV1, rAAV5, rAAV8, rAAV9, but also with rAAV-rh10, and
rAAV-hu11 (Davidson et al., 2000; Foust et al., 2009; Aschauer
et al., 2013; Petrosyan et al., 2014; Watakabe et al., 2015). AAV-
rh43 was found to produce fairly selective astroglial infection
(Lawlor et al., 2009), and further improvements in astrocytic
selectivity have been accomplished using rAAV5, rAAV8, and
rAAV-rh43, which expressed gene constructs under the control
of the astrocytic promoter Gfa2 (Lawlor et al., 2009; Drinkut
et al., 2012; Merienne et al., 2013). Discrepancies between glial
tropism of rAAV constructs in different studies may be due
to a number of reasons, including reported variability amongst
brain regions, with animal age, and species (Burger et al., 2004;
Foust et al., 2009; Aschauer et al., 2013; Weinberg et al., 2013).
Furthermore, even the methods of packaging and purification
may have a strong impact on the viral infectivity and astrocytic
tropism (Klein et al., 2008). Potential effects on cell type tropism
from different universal promoters and other integrated genetic
elements are also possible but have not been systematically
studied.
Here, we report high astrocytic transduction rates and fairly
strong astrocyte selectivity for a relatively understudied AAV
serotype, rAAV6. Few previous publications, which compared
different AAVs, have shown that rAAV6 has the propensity to
successfully transduce brain tissue in mice, rats, and primates
(Koerber et al., 2009; Blits et al., 2010; Markakis et al., 2010;
Aschauer et al., 2013). rAAV6 affinity for astrocytes appears to
vary between brain regions from low to relatively high (Koerber
et al., 2009; Aschauer et al., 2013). In a separate study, rAAV6
constructs have also been used to infect malignant cells of human
glioblastoma multiforme, which arise from astrocytes (Huszthy
et al., 2005). In contrast to the brain, rAAV6 has been better
characterized in peripheral tissues, and demonstrated a high
capacity for transducing airway epithelial cells, cardiac tissue,
and skeletal muscles (Halbert et al., 2001; Blankinship et al.,
2004; Palomeque et al., 2007). Overall, the existing literature
contains precedents for astrocytic transduction by rAAV6, but
has not provided conclusive evidence of the relative tropism of
this serotype for neurons and astrocytes.
What factors may determine rAAV6 cell type tropism? The
bulk of our experiments have been carried out with rAAVs, which
differed only in their capsid proteins and were packaged and
purified in an identical manner at the same facility. Therefore,
the differences in astrocytic tropism are likely determined by
capsid protein structure. Although we did not pursue further the
molecular underpinnings for this phenomenon, some inferences
may be made based on the already existing literature. Several
studies found that AAV1 and AAV6, which have structurally
similar (∼99% homologous) capsid proteins, use α2,3 and α2,6
N-linked sialic acid moieties of the cell surface proteoglycans
for entry (Wu et al., 2006c; Huang et al., 2016). In the present
work, we found a strong dissimilarity between rAAV1 and rAAV6
in terms of their efficacy to transduce primary rat astrocytes in
cell culture. Such strong divergence between rAAV1 and rAAV6
tropism is unexpected, but not unprecedented. In several prior
publications, these two serotypes also demonstrated quite distinct
infection profiles when delivered into the brain and the heart,
or used for infection of liver cells in vitro (Wu et al., 2006a;
Markakis et al., 2010; Zincarelli et al., 2010). A likely explanation
is provided by the observation on the pivotal role for a few
unique amino acid residues within the AAV6 capsid components
(Wu et al., 2006a). The triple mutation Y731F/Y705F/T492V in
the rAAV6 capsid protein dramatically modified cell tropism
and efficacy for transducing microglial cells (Rosario et al.,
2016).
The significance of the present study is in identifying a
new tool for manipulating gene expression in astrocytes. To
date, astrocyte-specific gene transduction was reported with
“canonical” rAAV5, rAAV8, and rAAV9 driving gene expression
under control of the astrocytic Gfa2 promoter (see for example
Young et al., 2014; Furman et al., 2016). However, astrocytic
tropism of rAAV5, rAAV8, and rAAV9 may be strongly
influenced by packaging or other factors. To illustrate this point,
in our hands, rAAV5, rAAV8, and rAAV9 vectors acquired
from ViGene Biosciences produced low-to-undetectable GFP
expression in primary astrocyte cultures, but readily infected
ARPE-19 cells. Other studies utilized the recently discovered
preferential astrocytic tropism of rhAAV43, or the recombinant
AAV species in which capsid proteins were genetically modified
to increase astrocytic targeting (Koerber et al., 2009; Lawlor
et al., 2009). However, even in these cases the levels of astrocytic
infection were not necessarily high, with only a fraction of
astroglial cells expressing transgene proteins. For example, the
AAV mutants, which were engineered to enhance glial delivery,
infected only ∼15% of astrocytes in vivo (Koerber et al., 2009).
In the present work, we found very robust virus-driven GFP
expression in >90% of astrocytes in the brain areas infected with
rAAV6. At the very least, this is a strong starting point in design
and production of more refined vectors.
Keeping in mind the high variability of the past results
obtained with rAAVs from various packaging facilities, the
looming question is whether the data presented in the current
manuscript can be consistently reproduced by others in the
field. We attempted to address these concerns through several
lines of extensive in vitro and in vivo experiments. Astrocytic
transduction was initially evaluated with several batches of
rAAVs in the primary rat astrocytes. Viability of all “ineffective”
or “less effective” rAAV constructs was validated in the same
viral batches using human ARPE-19 cells, which are known to
be transduced by numerous rAAVs. The cell type (astrocytic)
tropism of rAAV6 was quantitatively tested in vivo in several
animals, and the results were reproduced with different viral
preparations to account for potential inter-batch variability.
Finally, quantification of viral tropism was performed in a
blinded fashion to minimize the chance of analytical bias. The
rAAV6 constructs tested by us are available from a commercial
source, where they are produced through highly standardized
packaging and purification procedures. Therefore, rAAV6 can
serve as a new useful tool for manipulating gene expression in rat
astrocytes for all interested investigators, regardless of their prior
experience with AAV constructs.
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FIGURE S1 | Comparison of astrocytic transduction by rAAV serotypes 1,
2, and 5–9 obtained from a different viral packaging batch or from a
different packaging facility. Primary rat astrocytes were infected with 105
gc/cell of each serotype as indicated or not transfected (NTF). After 48 h, cells
were immunostained with the anti-GFP antibody to visualize viral expression and
stained with DAPI to visualize nuclei. rAAV1,2,5–9 were from ViGene Biosciences,
but from a different packaging batch as compared to the data presented in
Figure 1. Additionally, we used rAAV1 (AAV2/1), rAAV2 (AAV2/2), rAAV5 (AAV2/5),
and rAAV9 (AAV2/9) constructs from the University of Massachusetts Medical
School packaging facility. In these latter constructs, numerical designations stand
for the inverted terminal repeat regions sequences from AAV2 and capsids
proteins from AAV1, 2, 5, 9. Images were taken using an Olympus IX71 inverted
microscope at 100× magnification with identical exposure settings. See “Materials
and Methods” for additional information on viral composition and staining details.
FIGURE S2 | Propagation of viral transduction in the brains infected with
rAAV2 or rAAV6. Immunohistochemical images of the coronal sections from a
representative animal injected with rAAV2 (left column) or an animal injected with
rAAV6 (Right column). The 25-µm coronal sections were stained with anti-GFP
antibody and counterstained with DAPI. Low magnification fluorescence images
were captured using a Zeiss Axio Imager.M2 microscope at 50× magnification;
and multiple fields from the same section were stitched together using
NeuroLucida software. The anatomical hallmarks in each section are represented
by drawings prepared based on the atlas by G. Paxinos and C. Watson. “The Rat
Brain” (sixth edition). INSETS show matching high magnification images from the
same sections, in which GFP fluorescence was captured with a Zeiss LSM510
META confocal microscope at 250× magnification (Scale bars = 50 µm). An
approximate position of each inset image on coronal sections is indicated by
green arrows.
FIGURE S3 | Representative images of the AAV2- (Left) and AAV6- (Right)
injected rat brains captured at low magnification. 25-µm brain sections were
stained with the anti-GFP antibody to visualize viral transduction. Lower panels
show digitally magnified fields from the selected areas. Red arrowheads point to
representative neuronal-like cells. Yellow arrows point to cells with astrocytic
morphology. Images were taken close to the injection site at identical 100×
magnification and exposure settings using an Olympus IX71 inverted microscope.
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